Drug Profile
Research programme: peptide diagnostics - Soricimed
Alternative Names: SOR-C27-Cy5.5; SOR-D01; SOR-D02; Soricidin-based C-series peptide diagnosticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Soricimed Biopharma
- Class Peptide diagnostics
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ovarian-cancer(Diagnosis) in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in Canada
- 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer(Diagnosis) in Canada